SA-001
- Generic Name
- SA-001
Clinical Study to Investigate the Systemic Exposure, Safety, and Local Tolerability of SJP002 Ophthalmic Solution in Healthy Male Volunteers
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT02924155
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine Insufficiency
Phase 3
Completed
- Conditions
- Pancreatic Exocrine Insufficiency, Chronic Pancreatitis, Pancreatectomy
- Interventions
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- Abbott
- Target Recruit Count
- 80
- Registration Number
- NCT00401076
- Locations
- π―π΅
Site Reference ID/Investigator# 45220, Hiroshima, Japan
π―π΅Site Reference ID/Investigator# 45213, Kanagawa, Japan
π―π΅Site Reference ID/Investigator# 45282, Miyagi, Japan
A Study of SA-001 to Treat Pancreatic Exocrine Insufficiency
Phase 3
Completed
- Conditions
- Exocrine Pancreatic Insufficiency, Chronic Pancreatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2011-07-28
- Lead Sponsor
- Abbott
- Target Recruit Count
- 274
- Registration Number
- NCT00400842
- Locations
- π―π΅
Site Reference ID/Investigator# 59984, Amori, Japan
π―π΅Site Reference ID/Investigator# 59572, Fukuoka, Japan
π―π΅Site Reference ID/Investigator# 59845, Aichi, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath